Cysteine (the reduced form of the amino acid Cystine) is generally considered relevant for foundational metabolic support and plays a role in supporting the body's protective functions. A core, officially recognized use is in nutritional support for specific patient populations. A form of Cysteine is indicated for use as an additive to amino acid solutions for Total Parenteral Nutrition (TPN). This application is relevant when supportive symptom management is appropriate and assists with maintaining functional stability in settings marked by temporary physiological imbalance.

Common clinical scenarios involving Cysteine derivatives include acting as an antidote for acetaminophen (paracetamol) overdose and for its mucolytic properties. These uses may assist with managing symptoms related to systemic imbalance or inflammatory states in the respiratory tract. One key benefit is that: “It offers symptomatic relief that helps patients cope more steadily” during difficult episodes by easing distress.

Quick Fact: Supportive management for symptoms of inflammatory or irritative states.

Regulatory References

1. NIH DailyMed for Cysteine Injection

Who Can and Cannot Use Cysteine Hydrochloride Injection?

---

The eligibility profile for Cysteine Hydrochloride Injection, a nutritional additive for Total Parenteral Nutrition (TPN), is strictly defined by regulatory criteria.

Populations Allowed

The product is explicitly indicated for use in neonates (preterm and term infants) and pediatric patients who require TPN for nutritional support. Use is also permitted in adult patients with severe liver disease needing TPN.

Absolute Contraindications

This medicine is contraindicated and must not be used in several groups. These include patients with a known hypersensitivity to one or more amino acids or with inborn errors of amino acid metabolism. Absolute non-eligibility also applies to patients experiencing hepatic coma, or those with pulmonary edema or acidosis resulting from low cardiac output.

Restricted and Not-Established Use

Administration requires caution and frequent monitoring in patients with renal impairment or hepatic impairment. Severe fluid, electrolyte, and acid-base disorders must be corrected prior to use. Furthermore, the safety and efficacy have not been established for the geriatric population or the general adult population.

Interactions with other medicines and products

Regulatory documentation for the medicinal derivatives of Цистин ( Cysteine and N-Acetylcysteine) describes interaction patterns focused on physical compatibility and pharmacodynamic effects, rather than metabolic enzyme pathways.

Administration and Compatibility Constraints

Interacting Substance	Official Restriction Description
Calcium and Phosphate salts	Co-addition with Cysteine in TPN solutions requires a strict mixing sequence to prevent calcium phosphate precipitates and the associated risk of embolism.
Other Drugs in a nebulizer	Mixing N-Acetylcysteine solution with other drugs is restricted because the stability and safety of the combined mixture have not been established.
Activated Charcoal	Administration must be separated to avoid the physical binding that reduces the therapeutic effect of N-Acetylcysteine as an antidote.
Tetracycline	Concurrent use with Cysteine-containing solutions may reduce the nitrogen sparing effects of the amino acids.

Pharmacodynamic Effects

Interacting Substance	Official Interaction Outcome
Nitroglycerin	Co-administration with N-Acetylcysteine is documented to result in significant hypotension (low blood pressure) and temporal artery dilation.
Antitussive Drugs	Co-administration is generally not recommended as the reduction of the cough reflex may lead to a buildup of bronchial secretions.

Direct Molecular Transformation via Thiol-Disulfide Exchange

This mechanism operates at the molecular level, centered on a thiol-disulfide exchange reaction where the drug's sulfhydryl ( -SH) group chemically targets and cleaves the disulfide bond of the poorly soluble cystine dimer in the urine. This action initiates a mechanistic cascade by forming a new Cysteine-Drug Mixed Disulfide Complex. This chemical conversion represents the primary mechanism of operation, bypassing receptor and enzyme systems entirely.

Urinary Solubility and Supersaturation Management

The new chemical complex is highly water-soluble compared to native cystine. This high solubility fundamentally alters the urinary chemical equilibrium, preventing the renal filtrate from reaching a state of supersaturation with crystal-forming components. This management of the solubility pathway leads to the functional consequence of preventing the transition of cystine from a dissolved state to a solid crystalline state, thereby facilitating the excretion of the cystine load from the body in a dissolved state.

pH-Constrained Mechanistic Efficacy

The execution of this molecular transformation is constrained by the chemical environment, placing it within a pH-dependent efficacy domain. The necessary thiol-disulfide exchange reaction is maximized only when the urine is maintained in an alkaline state (typically pH > 7.0). This external chemical factor is required for the mechanism to maximize its effect on solubilization.

How to Use Cysteine Hydrochloride Injection (Цистин)

This section outlines the official instructions for the preparation and administration of Cysteine Hydrochloride Injection, which is used as an additive in parenteral nutrition (PN) solutions.

Administration Procedure

Cysteine Hydrochloride Injection is administered via intravenous infusion and is not a drug that is injected directly or taken orally. It must first be diluted and compounded into a complete PN solution using strict aseptic techniques. The final solution must be prepared by a qualified healthcare professional.

Administration Scope	Official Instruction
Route of Administration	Intravenous infusion, as an admixture in parenteral nutrition solutions.
Dosing Schedule	Individualized; based on the patient's condition, weight, and nutritional needs. Specific formulas apply to different age groups.
Timing/Condition	Continuous infusion as part of a Total Parenteral Nutrition (TPN) regimen. The final solution must be infused within 24 hours of preparation.

Official Compounding Steps

The preparation involves a specific sequence of steps to ensure the stability and safety of the final solution.

1. Preparation: A calculated volume of the Cysteine Hydrochloride Injection is transferred to an amino acid solution under aseptic conditions.
2. Admixing Sequence: The Cysteine/amino acid mixture is then combined with other components (such as dextrose, electrolytes, and trace elements) following a rigid mixing sequence to prevent precipitation.
3. Inspection: The final PN solution must be gently agitated and inspected for any visible precipitates before use. Solutions with an osmolarity of 900 mOsm/L or greater must be administered via a central venous catheter.

This regulated process ensures the correct and standardized use of the component as defined in the official labeling documents.

Research Evidence / Overview of Studies for Цистин

---

Evidence for Use in Nutritional Support

Research has explored how the amino acid L-Cysteine was evaluated for nutritional support, particularly when patients receive all their nutrients intravenously through Total Parenteral Nutrition ( TPN). Studies focused primarily on vulnerable patient groups, such as preterm and term infants. These investigations were designed as short-term, randomized controlled trials ( RCTs) to monitor fundamental metabolic markers. Studies reported measurements showing different patterns of nitrogen retention when L-Cysteine was included in the TPN solution compared to those without it. However, the follow-up durations were limited, typically lasting only a few weeks.

Evidence for Management Strategies in Cystinuria

Cystine was studied for its role in Cystinuria, a rare, genetic condition characterized by a buildup of the amino acid leading to kidney stones. The evidence relies on observational cohort studies and long-term case series of affected individuals. Research examined approaches that aim to make Cystine more soluble in the urine, such as modifying urinary pH. The primary research focus is on the consequences of high urinary Cystine and the secondary approaches that were evaluated to increase Cystine excretion or solubility. A limitation is that comparative evidence is lacking from large, controlled prospective trials.

Studies on Supportive Metabolic Balance

Research examined whether Cystine or its close derivatives, such as N-acetylcysteine ( NAC), affect markers of systemic or functional imbalance. These short-term RCTs primarily focused on measuring changes in antioxidant biomarkers, such as Glutathione levels, rather than measuring patient-reported outcomes. Findings describe patterns observed in the studies related to these biomarker shifts, but results were often mixed. The connection between these lab findings and meaningful, long-term patient-reported experiences is not fully established, and certainty remains low for many applications.

Key Studies & References

1. Cysteine Hydrochloride Injection, USP Solution label, 50 mg/mL

Common questions about Цистин (FAQ)

Q: Can women who are pregnant or breastfeeding use Цистин, according to official guidelines?

Official product information places this medicine in Pregnancy Category C, indicating that animal reproduction studies have not been conducted. The medicine is generally used when a healthcare professional determines the potential benefit is necessary and outweighs the potential risks to the fetus. Regarding breastfeeding, the safety of the drug and the risk of its excretion into human milk are not currently established in the regulatory documents.

---

Q: Are there any specific foods or drinks that should be avoided when taking Цистин?

The official documentation indicates that this medicine is administered as an intravenous infusion (directly into the vein) as a component of a total parenteral nutrition (TPN) solution. Since the drug is not taken orally, specific oral food or drink interactions are generally not a documented concern.

---

Q: Does Цистин carry a risk of long-term side effects?

The official safety documentation includes a warning that prolonged parenteral administration (long-term IV use), particularly in vulnerable patients such as preterm infants or those with impaired kidney function, carries an increased risk of Aluminum Toxicity. This toxicity may affect the central nervous system and bone health. Regulatory documents indicate that use of this product often involves close monitoring to manage potential systemic risks.

---

Q: What are the most commonly reported side effects listed in official documents for Цистин?

According to the official safety information, some of the most commonly documented adverse reactions include a warm sensation, redness, or phlebitis (vein inflammation) at the infusion site, as well as generalized flushing, fever, and nausea.

---

Q: Is it true that Цистин is primarily used for conditions involving the kidneys?

The drug product, Cysteine Hydrochloride Injection, is formally indicated as a nutritional additive for patients requiring Total Parenteral Nutrition (TPN). Separately, the chemical component, Cystine, and its molecular mechanism of action are highly relevant to the management of kidney-related conditions like Cystinuria. The mechanism of the chemical component is linked to kidney function, which is distinct from the primary formal indication of the Cysteine Hydrochloride Injection drug product.

---

Q: How is the required duration of Цистин treatment typically determined?

Official dosage and administration instructions state that the duration of use is determined based on the patient's nutritional requirements, body weight, clinical condition, and the overall length of time they require Total Parenteral Nutrition (TPN). The prescribed course of treatment is based on these factors.

---

Q: Is it normal to feel slightly nauseous when first starting to take Цистин?

The official safety information confirms that nausea is a documented possibility and is listed among the common adverse reactions reported. Patients experiencing this or other side effects should adhere to their treatment plan and discuss any concerns with a healthcare professional.

---

Q: How does the official literature describe the expected outcome of treatment with Цистин?

The primary expected outcome, as stated in the official Indications and Usage, is to successfully meet the intravenous amino acid nutritional requirements of the indicated patient population. This describes the drug's role as a component intended to meet specific nutritional requirements in total parenteral feeding regimens.

---

Q: Is Цистин available without a prescription in any region?

According to official regulatory classifications, this product is marked as 'Rx' (prescription only). The medicine is specifically intended for specialized admixture and administration as an intravenous infusion, a procedure that requires oversight and preparation by a qualified healthcare professional.

---

Q: Are there different forms or strengths of the Цистин drug that people take?

The drug product described in official regulatory documents is specified as an Injection, with a listed strength of 500 mg/10 mL (or 50 mg/mL). Official documents for Cysteine Hydrochloride focus only on this specific parenteral form used as an additive.

---

Q: Are there any mental or mood-related side effects linked to Цистин?

The official safety section contains warnings about severe adverse reactions that may have systemic effects. Specifically, severe Hepatobiliary Disorders and the risk of Aluminum Toxicity have been linked to potential effects on the central nervous system and neurocognitive delay in vulnerable patient groups.

---

Q: What are the typical non-serious side effects associated with starting Цистин?

The typical, less severe side effects documented in the official safety information are often related to the infusion process itself. These documented reactions include localized discomfort at the injection site, such as a warm sensation or temporary redness.

How to Store and Dispose of L-Cystine (Цистин)

Storage and disposal must strictly adhere to the official conditions defined in regulatory labeling to ensure product stability and safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), avoiding excessive heat.
Protection	Protect from moisture and direct light; store in a dry place. Do not freeze the product.
Container	Keep the medicine in its original container and ensure it is tightly closed when not in use.
Child Safety	The product must be stored out of the reach and sight of children and pets.

---

Disposal Instructions

Unused or expired L-Cystine should be disposed of through a medicine take-back program or authorized collection site. If a program is unavailable, follow the official guidelines for household trash disposal by mixing the medicine with an undesirable substance before sealing and discarding it. Do not flush the medicine down the toilet unless the official label explicitly permits this method.